Emerging research suggest Retatrutide , a dual activator targeting both incretin and another hormone, may represent a notable step forward for weight management . Preliminary clinical investigations have indicated substantial decreases in visceral tissue, potentially exceeding current obesity therapies . Nevertheless , more study is necessary to th